- Report
- February 2024
- 150 Pages
Global
From €4564EUR$4,750USD£3,918GBP
From €6245EUR$6,500USD£5,361GBP
- Report
- February 2024
- 150 Pages
Global
From €4564EUR$4,750USD£3,918GBP
- Report
- August 2023
- 145 Pages
Global
From €3027EUR$3,150USD£2,598GBP
- Report
- February 2024
- 90 Pages
Asia Pacific
From €4564EUR$4,750USD£3,918GBP
- Report
- February 2024
- 80 Pages
Latin America
From €4564EUR$4,750USD£3,918GBP
- Report
- February 2024
- 80 Pages
Europe
From €4564EUR$4,750USD£3,918GBP
- Report
- February 2024
- 70 Pages
North America
From €4564EUR$4,750USD£3,918GBP
- Report
- February 2024
- 70 Pages
Europe
From €4564EUR$4,750USD£3,918GBP
- Report
- February 2024
- 70 Pages
Asia Pacific
From €4564EUR$4,750USD£3,918GBP
- Report
- February 2024
- 70 Pages
Latin America
From €4564EUR$4,750USD£3,918GBP
- Report
- February 2024
- 70 Pages
United States
From €4564EUR$4,750USD£3,918GBP
- Report
- August 2023
- 70 Pages
Middle East, Africa
From €4564EUR$4,750USD£3,918GBP
- Report
- August 2023
- 150 Pages
North America
From €4564EUR$4,750USD£3,918GBP
- Report
- February 2021
- 500 Pages
United States
From €2306EUR$2,400USD£1,980GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4564EUR$4,750USD£3,918GBP
- Report
- February 2024
- 70 Pages
South Africa
From €4564EUR$4,750USD£3,918GBP
- Report
- February 2024
- 70 Pages
Indonesia
From €4564EUR$4,750USD£3,918GBP
- Report
- February 2024
- 70 Pages
Philippines
From €4564EUR$4,750USD£3,918GBP
- Report
- February 2024
- 70 Pages
India
From €4564EUR$4,750USD£3,918GBP
Linagliptin is a drug used to treat type 2 diabetes, a condition in which the body does not produce enough insulin or does not use insulin properly. It belongs to a class of drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors, which work by increasing the amount of insulin released by the pancreas. Linagliptin is used in combination with diet and exercise to improve glycemic control in adults with type 2 diabetes. It is also used to reduce the risk of cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
Linagliptin is part of the Endocrine and Metabolic Disorders Drugs market, which includes drugs used to treat conditions such as diabetes, obesity, and thyroid disorders. These drugs are used to control blood sugar levels, reduce cholesterol, and regulate hormones.
Companies in the Linagliptin market include Boehringer Ingelheim, Merck, Novartis, and Eli Lilly. Show Less Read more